// App-Quantinova.ai

OP0302 : IANALUMAB (VAY736), A DUAL MODE OF ACTION BIOLOGIC COMBINING BAFF RECEPTOR INHIBITION WITH B CELL DEPLETION, REACHES PRIMARY ENDPOINT FOR TREATMENT OF PRIMARY SJOGREN’S SYNDROME

Researchers

Presenter

  • T. Drner

Principal Investigators

  • S. J. Bowman

  • R. Fox

  • X. Mariette

  • A. Papas

  • T. Grader-Beck

  • B. A. Fisher

  • F. Barcelos

  • S. De Vita

  • H. Schulze-Koops

  • R. J. Moots

  • G. Junge

  • J. Woznicki

  • M. Sopala

  • W. L. Luo

  • W. Hueber

Medical Centers

  • Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany

  • Department of Haematology, University Hospitals NHS Foundation Trust, Bristol, United Kingdom

  • Scripps Memorial Hospital and Research Institute, CA 92121, United States of America

  • University Paris-Sud, Paris, France

  • Division of Oral Medicine, Tufts School of Dental Medicine, Massachusetts, United States of America

  • Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, United States

  • University of Birmingham, Birmingham, United Kingdom

  • NIHR Birmingham Biomedical Research Centre, Rheumatology, Birmingham, United Kingdom

  • Instituto Portugues de Oncologia de Lisboa, Lisbon, Portugal

  • Department of Medicine (DAME) - University of Udine, Udine, Italy

  • Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany

  • Department of Gastroenterology, University of Liverpool, Liverpool, United Kingdom

  • Novartis AG, Basel, Switzerland

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

Locations

  • Germany

  • United Kingdom

  • United States

  • France

  • Portugal

  • Italy

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Sjogren's syndrome

Biomarkers

  • B-cell activating factor

Drug/Treatment

  • Methylprednisolone

  • VAY736

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • II

Study Id's

  • N/A

Sponsors

  • Janssen Pharmaceutical

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved